<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">J Vet Med Sci</journal-id>
      <journal-id journal-id-type="iso-abbrev">J. Vet. Med. Sci</journal-id>
      <journal-id journal-id-type="publisher-id">JVMS</journal-id>
      <journal-title-group>
        <journal-title>The Journal of Veterinary Medical Science</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0916-7250</issn>
      <issn pub-type="epub">1347-7439</issn>
      <publisher>
        <publisher-name>The Japanese Society of Veterinary Science</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">23955394</article-id>
      <article-id pub-id-type="pmc">3942949</article-id>
      <article-id pub-id-type="publisher-id">12-0503</article-id>
      <article-id pub-id-type="doi">10.1292/jvms.12-0503</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Internal Medicine</subject>
          <subj-group>
            <subject>Note</subject>
          </subj-group>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Unsuccessful Cyclosporine plus Prednisolone Therapy for Autoimmune
Meningoencephalitis in Three Dogs</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>JUNG</surname>
            <given-names>Dong-In</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>LEE</surname>
            <given-names>Hee-Chun</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>HA</surname>
            <given-names>Jeongim</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>JUNG</surname>
            <given-names>Hae-Won</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>JEON</surname>
            <given-names>Joon-Hyeok</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>MOON</surname>
            <given-names>Jong-Hyun</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>LEE</surname>
            <given-names>Jae-Hoon</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>KIM</surname>
            <given-names>Na-Hyun</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>SUR</surname>
            <given-names>Jung-Hyang</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>KANG</surname>
            <given-names>Byeong-Teck</given-names>
          </name>
          <xref ref-type="aff" rid="aff3">
            <sup>3</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>CHO</surname>
            <given-names>Kyu-Woan</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
          <xref rid="cor1" ref-type="corresp">
            <sup>*</sup>
          </xref>
        </contrib>
        <aff id="aff1"><label>1)</label>Research Institute of Life Sciences, College of Veterinary
Medicine, Gyeongsang National University, Jinju 660&#x2013;701, South Korea</aff>
        <aff id="aff2"><label>2)</label>Department of Pathobiology, Small Animal Tumor Diagnostic
Center, College of Veterinary Medicine, Konkuk University, Seoul 143&#x2013;701, South
Korea</aff>
        <aff id="aff3"><label>3)</label>Laboratory of Veterinary Dermatology and Neurology, College
of Veterinary Medicine, Chungbuk National University, Cheongju, Chungbuk 361&#x2013;763, South
Korea</aff>
      </contrib-group>
      <author-notes>
        <corresp id="cor1"><label>*</label>Correspondence to: Cho, K.-W., Research Institute of Life
Sciences, College of Veterinary Medicine, Gyeongsang National University, Jinju 660&#x2013;701,
South Korea. e-mail: <email xlink:href="chokw@gnu.ac.kr">chokw@gnu.ac.kr</email></corresp>
      </author-notes>
      <pub-date pub-type="epub">
        <day>13</day>
        <month>8</month>
        <year>2013</year>
      </pub-date>
      <pub-date pub-type="ppub">
        <month>12</month>
        <year>2013</year>
      </pub-date>
      <volume>75</volume>
      <issue>12</issue>
      <fpage>1661</fpage>
      <lpage>1665</lpage>
      <history>
        <date date-type="received">
          <day>15</day>
          <month>11</month>
          <year>2012</year>
        </date>
        <date date-type="accepted">
          <day>30</day>
          <month>7</month>
          <year>2013</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9;2013 The Japanese Society of Veterinary Science</copyright-statement>
        <copyright-year>2013</copyright-year>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-nd/3.0/">
          <license-p>This is an open-access article distributed under the terms of the Creative
Commons Attribution Non-Commercial No Derivatives (by-nc-nd) License. </license-p>
        </license>
      </permissions>
      <abstract>
        <title>ABSTRACT</title>
        <p>A 4-year-old female Maltese (case 1), a 9-year-old castrated male shih tzu (case 2) and
2-year-old female Pomeranian (case 3) presented with neurological signs, such as head
tilt, ataxia, circling and paresis. The three cases were tentatively diagnosed as having
meningoencephalitis of unknown etiology based on computed tomography scan and
cerebrospinal fluid analysis. All patients were managed with cyclosporine plus
prednisolone therapy. The survival times of the three patients were 170, 70 and 21 days,
respectively. After the cases died, we performed necropsy and histopathological
examination for definitive diagnosis. Based on the necropsy, histopathological and
immunohistochemical examinations, cases 1, 2 and 3 were definitely diagnosed as having
necrotizing meningoencephalitis, necrotizing leukoencephalitis and granulomatous
meningoencephalitis, respectively. This case report demonstrated the clinical findings,
brain CT characteristics and histopathological and immunohistochemical features of NME,
NLE and GME in dogs and discussed the reason for the relatively short survival times under
cyclosporine plus prednisolone therapy.</p>
      </abstract>
      <kwd-group>
        <kwd>canine</kwd>
        <kwd>cyclosporine</kwd>
        <kwd>granulomatous meningoencephalitis (GME)</kwd>
        <kwd>necrotizing leukoencephalitis (NLE)</kwd>
        <kwd>necrotizing meningoencephalitis (NME)</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <p>Granulomatous meningoencephalitis (GME), necrotizing meningoencephalitis (NME) and
necrotizing leukoencephalitis (NLE) are common idiopathic autoimmune inflammatory disorders of
the central nervous system (CNS) in canine patients [<xref rid="r2" ref-type="bibr">2</xref>,
<xref rid="r7" ref-type="bibr">7</xref>, <xref rid="r10" ref-type="bibr">10</xref>, <xref rid="r12" ref-type="bibr">12</xref>, <xref rid="r18" ref-type="bibr">18</xref>, <xref rid="r20" ref-type="bibr">20</xref>, <xref rid="r21" ref-type="bibr">21</xref>]. In most
cases, a hypothetic antemortem diagnosis is achieved via a diverse examination that includes
assessment of clinical signs, cerebrospinal fluid (CSF) analysis, cross-sectional imaging of
the CNS via computed tomography (CT) scan or magnetic resonance imaging (MRI) and infectious
disease testing [<xref rid="r1" ref-type="bibr">1</xref>, <xref rid="r2" ref-type="bibr">2</xref>, <xref rid="r7" ref-type="bibr">7</xref>, <xref rid="r10" ref-type="bibr">10</xref>, <xref rid="r11" ref-type="bibr">11</xref>]. However, all CNS autoimmune
inflammation cases could be definitively diagnosed based on the results of histopathological
examination [<xref rid="r7" ref-type="bibr">7</xref>, <xref rid="r10" ref-type="bibr">10</xref>, <xref rid="r11" ref-type="bibr">11</xref>, <xref rid="r20" ref-type="bibr">20</xref>].</p>
    <p>Previous reports [<xref rid="r10" ref-type="bibr">10</xref>, <xref rid="r13" ref-type="bibr">13</xref>, <xref rid="r14" ref-type="bibr">14</xref>, <xref rid="r18" ref-type="bibr">18</xref>] have suggested that NME, NLE and GME are autoimmune CNS disorders and that
suppressing the immune reaction is the best management method for patients. Therefore, several
immunosuppressive drugs have been used for NME, NLE and GME cases [<xref rid="r1" ref-type="bibr">1</xref>, <xref rid="r2" ref-type="bibr">2</xref>, <xref rid="r6" ref-type="bibr">6</xref>, <xref rid="r9" ref-type="bibr">9</xref>,<xref rid="r10" ref-type="bibr">10</xref>,<xref rid="r11" ref-type="bibr">11</xref>, <xref rid="r23" ref-type="bibr">23</xref>]. Recently, several reports suggested that cyclosporine showed beneficial effects
for autoimmune CNS inflammatory cases [<xref rid="r1" ref-type="bibr">1</xref>, <xref rid="r2" ref-type="bibr">2</xref>, <xref rid="r9" ref-type="bibr">9</xref>,<xref rid="r10" ref-type="bibr">10</xref>,<xref rid="r11" ref-type="bibr">11</xref>].</p>
    <p>This case report demonstrates the clinical findings, brain CT characteristics and
histopathological and immunohistochemical features of NME, NLE and GME in dogs. It also
focuses on the discussion about the reason for the relatively short survival times under
cyclosporine plus prednisolone therapy in the present 3 cases.</p>
    <p>A 4-year-old female Maltese (case 1), a 9-year-old castrated male shih tzu (case 2) and
2-year-old female Pomeranian (case 3) presented with neurological signs, such as head tilt,
ataxia, circling and paresis. Case 1 showed acute progression of neurological defects, such as
left side head tilt, circling to the left side, blindness and ataxia. On physical and
neurological examination of case 1, open fontanelle; bilateral delayed postural reaction with
the left side being more severely affected than the right side; absence of menace response;
ventrolateral strabismus; left side head tilt; and left side circling were observed. Case 2
showed a 1 week history of neurological defect progression, such as tetraparesis (ataxia and
right side hemiparesis were initial signs) and head tilt. Prednisolone (1 mg/kg, PO, q 12 hr)
was administered for 7 days at a local animal hospital before presentation to us, but clinical
signs were not improved in case 2. On physical and neurological examination of case 2, left
side facial palsy, bilateral delayed postural reaction, absence of menace response and right
side head tilt were observed in the patient. Ataxia, right side facial palsy and right side
hemiparesis signs occurred 1 day before presentation in case 3. On physical and neurological
examination of case 3, right side facial palsy and delayed right side postural reactions were
observed. There were no remarkable findings with regard to blood tests (including complete
blood counts, serum biochemistry profiles, canine distemper virus RT-PCR in blood and
toxoplasma antigen detection by ELISA) and skull and thoracic radiography in all 3 cases.</p>
    <p>In case 1, moderate bilateral ventriculomegaly was found according to brain ultrasonography
via open fontanelle. We suggested brain CT examination to rule out encephalopathy, such as
congenital defects, CNS inflammation or brain tumor. However, the client refused brain CT
examination, because of the cost and anesthesia. Then, we prescribed prednisolone (1 mg/kg,
PO, q 12 hr) and furosemide (2 mg/kg, PO, q 12 hr) to case 1 and strongly recommended a brain
CT scan, if there was no response to the initial medication. The clinical signs gradually
improved after medication for 30 days. However, they were not eliminated and slowly worsened
after steroid tapering, because of severely increased hepatic enzyme levels (ALT, AST and ALP;
5&#x2013;6 times higher than the normal ranges) and severe polyuria/polydipsia/polyphagia (tapered to
0.5 mg/kg, PO, q 12 hr). About 70 days after initial presentation, the dog&#x2019;s clinical sings
were worse than at initial presentation, and the client decided to allow a brain CT
examination. In the CT findings, hypo-attenuated multifocal lesions were found in the right
cerebral cortex, and the lesions were not enhanced after contrast study (<xref ref-type="fig" rid="fig_001">Fig. 1A</xref><fig orientation="portrait" fig-type="figure" id="fig_001" position="float"><label>Fig. 1.</label><caption><p>Brain CT scan images (A, C, E) and necropsy findings (B, D, F) of the present cases.
Multifocal necrotic inflammatory lesions (arrows) are seen on CT and necropsy images
from case 1 (A &amp; B) and case 2 (C &amp; D). Edematous and inflammatory changes
(arrow) and falx cerebri deviation (small arrow) are seen on CT and necropsy images from
case 3 (E &amp; F).</p></caption><graphic xlink:href="jvms-75-1661-g001"/></fig>). The results of CSF analysis showed an increased nucleated cell count of 10
cells/<italic>&#xB5;l</italic> (reference range, 0&#x2013;5 cells/<italic>&#xB5;l</italic>). Cytologic
examination of the CSF revealed monocytic pleocytosis. The volume of CSF was not enough to
perform other tests, such as bacterial and fungal cultures, CDV RT-PCR and Toxoplasma ELISA,
so we could not proceed with other examinations of the CSF. Based on the examination results,
we tentatively diagnosed this case as meningoencephalitis of unknown etiology (MUE).
Management with prednisolone (Prednisolone, Korea Pharm., Seoul, Korea; 0.5 mg/kg, PO, q 12
hr) and cyclosporine microemulsion (CYPOL-N<sup>&#xAE;</sup>, Chong Kun Dang Pharm., Seoul, Korea;
6 mg/kg, PO, q 24 hr) was initiated, and clinical signs improved gradually compared with the
previous therapy (sole prednisolone therapy). Three weeks after cyclosporine administration,
ataxia and proprioceptive deficits had mildly progressed, and we prescribed a higher dose of
cyclosporine (10 mg/kg, PO, q 24 hr). Neurological signs were not improved, but had not
progressed. The clinical status of case 1 was maintained, but the dog suddenly died at home
100 days after cyclosporine administration (about 170 days after initial presentation).</p>
    <p>In cases 2 and 3, we could perform a brain CT examination at initial presentation. The CT
findings of case 2 showed hypo-attenuated lesions that were suspected to be necrotizing
lesions in both sides of cerebral cortex parts (<xref ref-type="fig" rid="fig_001">Fig.
1C</xref>). The CT findings of case 3 indicated that the falx cerebri had shifted to the
right side due to edematous changes of the left side cerebral parenchyma. Some parts of the
left cerebral cortex were enhanced after contrast study (<xref ref-type="fig" rid="fig_001">Fig. 1A</xref>). The results of CSF analysis showed an increased nucleated cell count of 20
cells/<italic>&#xB5;l</italic> (both cases 2 and 3; reference range, 0&#x2013;5
cells/<italic>&#xB5;l</italic>). Cytologic examination of the CSF revealed monocytic pleocytosis
(case 2) and lymphocytic pleocytosis (case 3). The volume of CSF was not enough to perform
other tests, such as bacterial and fungal cultures, CDV RT-PCR and Toxoplasma ELISA, so we
could not proceed with other examinations of CSF. Based on the examination results, we
tentatively diagnosed cases 2 and 3 as meningoencephalitis of unknown etiology (MUE). Then, we
started a combination therapy of prednisolone (1 mg/kg, PO, q 12 hr) and cyclosporine (6
mg/kg, PO, q 24 hr) for them. The clinical signs of both cases improved gradually after
medication, but were not eliminated. The clients of both cases had trouble with cyclosporine
administration at home and sometimes failed to give the medications. Cases 2 and 3 were
suddenly died at home 70 and 21 days after cyclosporine administration, respectively.</p>
    <p>In all 3 cases, necropsy and histopathological examination were performed after obtaining
consent from the owners. The findings of case 1 showed multifocal necrotic lesions in the
cerebral cortex, which was consistent with the CT findings (<xref ref-type="fig" rid="fig_001">Fig. 1B</xref>). The necropsy findings of case 2 also showed multifocal necrotic lesions in
the cerebral cortex (<xref ref-type="fig" rid="fig_002">Fig. 2B</xref><fig orientation="portrait" fig-type="figure" id="fig_002" position="float"><label>Fig. 2.</label><caption><p>Histopathological (HE stain; A, C, E) and immunohistochemical (anti CD 3 stain; B, D,
F) results of the present cases. A &amp; B: case 1; C &amp; D: case 2; E &amp; F: case
3. All cases represent T-cell-positive results around perivascular areas. Case 1, case 2
and case 3 were ultimately diagnosed as NME, NLE and GME, respectively.</p></caption><graphic xlink:href="jvms-75-1661-g002"/></fig>). Furthermore, an inflammatory lesion on the brainstem was noticed that had not been
found on the CT scan. The necropsy findings of case 3 revealed edematous changes of the left
cerebral parenchyma and lesions on the left cerebral cortex (<xref ref-type="fig" rid="fig_001">Fig. 1C</xref>). The histopathological examination results of cases 1 and 2
revealed neuronal necrosis, vacuolation and perivascular cuffing with lymphocyte infiltration
in the cerebral cortex, macrophage infiltration and necrosis in the white matter (<xref ref-type="fig" rid="fig_002">Fig. 2A and 2C</xref>). The lesion on the brainstem in case 2
also showed necrotic inflammatory changes. The histopathological examination results of case 3
demonstrated perivascular cuffing with lymphocyte infiltration in the cerebral cortex, but no
necrotic changes were found (<xref ref-type="fig" rid="fig_002">Fig. 2E</xref>).</p>
    <p>The immunohistochemistry results for T cells (anti CD3) in all 3 cases showed that positive
cells had infiltrated around vessels (<xref ref-type="fig" rid="fig_002">Fig. 2B, 2D and
2F</xref>). According to the histopathological and immunohistochemical findings, we
definitively diagnosed cases 1, 2 and 3 as NME, NLE and GME, respectively.</p>
    <p>GME, NME and NLE are common idiopathic CNS inflammation disorders in dogs [<xref rid="r1" ref-type="bibr">1</xref>, <xref rid="r5" ref-type="bibr">5</xref>, <xref rid="r7" ref-type="bibr">7</xref>, <xref rid="r11" ref-type="bibr">11</xref>, <xref rid="r13" ref-type="bibr">13</xref>, <xref rid="r14" ref-type="bibr">14</xref>, <xref rid="r17" ref-type="bibr">17</xref>, <xref rid="r18" ref-type="bibr">18</xref>, <xref rid="r20" ref-type="bibr">20</xref>]. GME is also thought to be an autoimmune disorder and
characterized histologically by perivascular cuffing with mononuclear cells in the CNS [<xref rid="r7" ref-type="bibr">7</xref>, <xref rid="r14" ref-type="bibr">14</xref>, <xref rid="r17" ref-type="bibr">17</xref>, <xref rid="r20" ref-type="bibr">20</xref>]. Necrotizing
CNS inflammation includes two pathologically distinct diseases referred to as NME and NLE
[<xref rid="r7" ref-type="bibr">7</xref>]. Both diseases are thought to be autoimmune
disorders and have similar characteristic features, such as multiple cavitary necrotic
nonsuppurative inflammatory brain lesions in gray and white matters [<xref rid="r7" ref-type="bibr">7</xref>, <xref rid="r20" ref-type="bibr">20</xref>].</p>
    <p>Most small breed dogs could be predisposed to GME [<xref rid="r7" ref-type="bibr">7</xref>].
NME and NLE have been reported mainly in the pug, Maltese, Pomeranian, Chihuahua, Yorkshire
terrier, shih tzu, Pekingese, West Highland white terrier, Boston terrier and miniature
pinscher [<xref rid="r7" ref-type="bibr">7</xref>, <xref rid="r10" ref-type="bibr">10</xref>,<xref rid="r11" ref-type="bibr">11</xref>,<xref rid="r12" ref-type="bibr">12</xref>,<xref rid="r13" ref-type="bibr">13</xref>, <xref rid="r18" ref-type="bibr">18</xref>, <xref rid="r22" ref-type="bibr">22</xref>].</p>
    <p>To date, the general treatment for autoimmune CNS inflammation in dogs has been
immunosuppressive doses of glucocorticoid [<xref rid="r7" ref-type="bibr">7</xref>, <xref rid="r11" ref-type="bibr">11</xref>]. However, the response to therapy with glucocorticoid
only varies, and clinical signs often relapse during the tapering of glucocorticoid therapy
[<xref rid="r7" ref-type="bibr">7</xref>, <xref rid="r10" ref-type="bibr">10</xref>, <xref rid="r11" ref-type="bibr">11</xref>]. Various immunosuppressive drugs in autoimmune CNS
inflammation cases have been reported previously, but limited [<xref rid="r1" ref-type="bibr">1</xref>, <xref rid="r2" ref-type="bibr">2</xref>, <xref rid="r6" ref-type="bibr">6</xref>,
<xref rid="r9" ref-type="bibr">9</xref>,<xref rid="r10" ref-type="bibr">10</xref>,<xref rid="r11" ref-type="bibr">11</xref>, <xref rid="r23" ref-type="bibr">23</xref>]. According
to several recent reports [<xref rid="r1" ref-type="bibr">1</xref>, <xref rid="r2" ref-type="bibr">2</xref>, <xref rid="r9" ref-type="bibr">9</xref>,<xref rid="r10" ref-type="bibr">10</xref>,<xref rid="r11" ref-type="bibr">11</xref>], cyclosporine and prednisolone
combination therapy allowed for a decrease in the dose of prednisolone and showed synergic
effects on autoimmune CNS inflammation. One study [<xref rid="r2" ref-type="bibr">2</xref>]
demonstrated that the median survival time after cyclosporine combination therapy in CNS
inflammation was 930 days. Another study [<xref rid="r15" ref-type="bibr">15</xref>] reported
that the median survival time of 15 GME dogs with sole prednisolone therapy was 41 days. In
one previous report [<xref rid="r11" ref-type="bibr">11</xref>], moreover, the mean survival
time of histopathologically confirmed NME dogs with cyclosporine plus prednisolone therapy was
305.7 &#xB1; 94.7 days, and the mean survival time of histopathologically confirmed NME dogs with
sole prednisolone therapy was 58.3 &#xB1; 30.5 days. Furthermore, one other report [<xref rid="r10" ref-type="bibr">10</xref>] described survival for 1,096 days after cyclosporine
plus prednisolone therapy in a histopathologically confirmed NME case. Although there were no
histopathologic confirmations, several reports [<xref rid="r1" ref-type="bibr">1</xref>, <xref rid="r9" ref-type="bibr">9</xref>] described cyclosporine therapy as showing beneficial
effects in autoimmune CNS inflammation suspected dogs.</p>
    <p>In this study, we administered cyclosporine plus prednisolone in three dogs with autoimmune
CNS inflammation. However, the survival times of the 3 dogs were relatively shorter than in
previous studies [<xref rid="r1" ref-type="bibr">1</xref>, <xref rid="r2" ref-type="bibr">2</xref>, <xref rid="r9" ref-type="bibr">9</xref>,<xref rid="r10" ref-type="bibr">10</xref>,<xref rid="r11" ref-type="bibr">11</xref>]. Just one case survived for 170 days,
and the other two cases survived less than 100 days after cyclosporine plus prednisolone
therapy in this study.</p>
    <p>There are several possible reasons for the shorter survival times in this study. 1) In case
1, the client refused a brain CT on the initial presentation day, and we just prescribed
prednisolone (1 mg/kg, PO, q 12 hr) plus furosemide (2 mg/kg, PO, q 12 hr) for 70 days.
According to our experiences, the timing of administration of immunosuppressants (as early as
possible) is very important to extend survival time in autoimmune CNS inflammation cases.
Prednisolone could cause improvement of inflammatory and edematous changes in almost all
autoimmune CNS inflammation cases, but it could not delay autoimmune disease progression at a
lower dose. Adverse effects, such as polyuria/polydipsia/polyphagia, hepatotoxicity, weight
gain, iatrogenic Cushing&#x2019;s disease and depression, are frequently seen during long-term
prednisolone therapy. According to a previous report [<xref rid="r10" ref-type="bibr">10</xref>], immunosuppressants, such as cyclosporine, could decrease the speed of disease
progression when used with an appropriate method and timing. We suspected that case 1 missed
the appropriate timing for administration of cyclosporine. Therefore, late cyclosporine
administration might not show an extremely beneficial effect like previous reports [<xref rid="r1" ref-type="bibr">1</xref>, <xref rid="r2" ref-type="bibr">2</xref>, <xref rid="r9" ref-type="bibr">9</xref>,<xref rid="r10" ref-type="bibr">10</xref>,<xref rid="r11" ref-type="bibr">11</xref>]. Although case 1 showed a relatively short survival
time, we should focus on improvement of clinical signs after cyclosporine administration
compared with the status when using prednisolone only therapy. 2) Because cyclosporine is
capsular emulsion form, it may be difficult to administer it by an appropriate method.
Moreover, one previous report [<xref rid="r19" ref-type="bibr">19</xref>] described that
administration of cyclosporine with food could decrease the bioavailability by 22% and
increase the individual variability of drug absorption. The owners of the cases 2 and 3 dogs
had serious trouble with cyclosporine administration at home and sometimes failed to give the
medications. Cyclosporine was administered less than 3 times in a week in both cases. Although
we used cyclosporine plus prednisolone initially for cases 2 and 3, both cases were acute
forms, and inconsistent administration of cyclosporine could not delay the disease
progression. Acute form autoimmune CNS inflammation progresses rapidly and shows high
mortality even in the early stage. According to a previous report [<xref rid="r10" ref-type="bibr">10</xref>], cyclosporine could not stop the progress of the disease but could
improve inflammatory and edematous changes initially and then decrease the speed of disease
progression. 3) We did not measure the cyclosporine concentration in the 3 cases, so we could
not show the exact therapeutic concentration after therapy.</p>
    <p>A limitation of this study is that we demonstrated our opinion based on previously published
clinical papers. However, it is necessary to provide a logical discussion, and more
randomized, controlled, blinded or large-scale studies are essential parts of this. None of
the previous clinical studies matched up with these concepts perfectly. More clinical trials
to compare the efficacy in autoimmune CNS inflammation are necessary to prove the better
effects of cyclosporine. However, it is also true that actually performing a clinical study
that perfectly fulfills the above needs is very difficult. Although each study consisted of a
small number of cases, collection of data from previous reports should not be ignored. It is
not entirely enough, but it could be somewhat presumptive evidence.</p>
    <p>Another limitation is the limited number of cases in this study. Several previous reports
[<xref rid="r3" ref-type="bibr">3</xref>, <xref rid="r4" ref-type="bibr">4</xref>, <xref rid="r8" ref-type="bibr">8</xref>, <xref rid="r16" ref-type="bibr">16</xref>, <xref rid="r19" ref-type="bibr">19</xref>] described the pharmacodynamics, pharmacokinetics and
clinical efficacy of cyclosporine in dogs. It is true that cyclosporine is the one of the
beneficial options for treating autoimmune CNS inflammations in dogs [<xref rid="r1" ref-type="bibr">1</xref>, <xref rid="r2" ref-type="bibr">2</xref>, <xref rid="r9" ref-type="bibr">9</xref>,<xref rid="r10" ref-type="bibr">10</xref>,<xref rid="r11" ref-type="bibr">11</xref>]. However, cyclosporine therapy can sometimes fail in clinical practice. In other
words, autoimmune CNS inflammation cases do not always show a good response to cyclosporine
therapy. This was the starting point of this study. In this study, we discussed about the
reason for the relatively short survival times of the three autoimmune CNS inflammation cases
under cyclosporine therapy. Unfortunately, the small number of cases in this study presents a
problem. This study could have provided more logical clinical data, if a large cohort of cases
had been utilized. More clinical trials and a large number of cases are needed.</p>
    <p>In summary, we suggested that drug administration timing, frequency and therapeutic
concentration measurement are very important to extend survival times and improve the life
quality in autoimmune CNS inflammation cases treated with cyclosporine. Thus, aggressive
initial cyclosporine therapy is needed in suspected cases of autoimmune CNS inflammation.</p>
  </body>
  <back>
    <ack>
      <title>Acknowledgment</title>
      <p>This research was supported by the Basic Science Research Program through the National
Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and
Technology (2011-0008358).</p>
    </ack>
    <ref-list>
      <title>REFERENCES</title>
      <ref id="r1">
        <label>1</label>
        <mixed-citation publication-type="journal"><person-group><name><surname>Adamo</surname><given-names>F. P.</given-names></name><name><surname>O&#x2019;Brien</surname><given-names>R. T.</given-names></name></person-group><year>2004</year>
<article-title>Use of cyclosporine to treat
granulomatous meningoencephalitis in three dogs</article-title>. <source><italic>J. Am.
Vet. Med. Assoc.</italic></source><volume>225</volume>:
<fpage>1211</fpage>&#x2013;<lpage>1216</lpage>. doi: <pub-id pub-id-type="doi">10.2460/javma.2004.225.1211</pub-id><pub-id pub-id-type="pmid">15521442</pub-id></mixed-citation>
      </ref>
      <ref id="r2">
        <label>2</label>
        <mixed-citation publication-type="journal"><person-group><name><surname>Adamo</surname><given-names>P. F.</given-names></name><name><surname>Rylander</surname><given-names>H.</given-names></name><name><surname>Adams</surname><given-names>W. M.</given-names></name></person-group><year>2007</year>
<article-title>Cyclosporin use in multi-drug therapy for
meningoencephalomyelitis of unknown aetiology in dogs</article-title>.
<source><italic>J. Small Anim. Pract.</italic></source><volume>48</volume>:
<fpage>486</fpage>&#x2013;<lpage>496</lpage>. doi: <pub-id pub-id-type="doi">10.1111/j.1748-5827.2006.00303.x</pub-id><pub-id pub-id-type="pmid">17617166</pub-id></mixed-citation>
      </ref>
      <ref id="r3">
        <label>3</label>
        <mixed-citation publication-type="journal"><person-group><name><surname>Allenspach</surname><given-names>K.</given-names></name><name><surname>R&#xFC;fenacht</surname><given-names>S.</given-names></name><name><surname>Sauter</surname><given-names>S.</given-names></name><name><surname>Gr&#xF6;ne</surname><given-names>A.</given-names></name><name><surname>Steffan</surname><given-names>J.</given-names></name><name><surname>Strehlau</surname><given-names>G.</given-names></name><name><surname>Gaschen</surname><given-names>F.</given-names></name></person-group><year>2006</year>
<article-title>Pharmacokinetics and clinical efficacy of
cyclosporine treatment of dogs with steroid-refractory inflammatory bowel
disease</article-title>. <source><italic>J. Vet. Intern.
Med.</italic></source><volume>20</volume>: <fpage>239</fpage>&#x2013;<lpage>244</lpage>.
doi: <pub-id pub-id-type="doi">10.1111/j.1939-1676.2006.tb02852.x</pub-id><pub-id pub-id-type="pmid">16594578</pub-id></mixed-citation>
      </ref>
      <ref id="r4">
        <label>4</label>
        <mixed-citation publication-type="journal"><person-group><name><surname>Archer</surname><given-names>T. M.</given-names></name><name><surname>Fellman</surname><given-names>C. L.</given-names></name><name><surname>Stokes</surname><given-names>J. V.</given-names></name><name><surname>Pinchuk</surname><given-names>L. M.</given-names></name><name><surname>Lunsford</surname><given-names>K. V.</given-names></name><name><surname>Pruett</surname><given-names>S. B.</given-names></name><name><surname>Langston</surname><given-names>V. C.</given-names></name><name><surname>Mackin</surname><given-names>A. J.</given-names></name></person-group><year>2011</year>
<article-title>Pharmacodynamic monitoring of canine
T-cell cytokine responses to oral cyclosporine</article-title>. <source><italic>J. Vet.
Intern. Med.</italic></source><volume>25</volume>:
<fpage>1391</fpage>&#x2013;<lpage>1397</lpage>. doi: <pub-id pub-id-type="doi">10.1111/j.1939-1676.2011.00797.x</pub-id><pub-id pub-id-type="pmid">22092633</pub-id></mixed-citation>
      </ref>
      <ref id="r5">
        <label>5</label>
        <mixed-citation publication-type="journal"><person-group><name><surname>Braund</surname><given-names>K. G.</given-names></name><name><surname>Vandevelde</surname><given-names>M.</given-names></name><name><surname>Walker</surname><given-names>T. L.</given-names></name><name><surname>Redding</surname><given-names>R. W.</given-names></name></person-group><year>1978</year>
<article-title>Granulomatous meningoencephalitis in six
dogs</article-title>. <source><italic>J. Am. Vet. Med.
Assoc.</italic></source><volume>172</volume>: <fpage>1195</fpage>&#x2013;<lpage>1200</lpage>
<pub-id pub-id-type="pmid">659301</pub-id></mixed-citation>
      </ref>
      <ref id="r6">
        <label>6</label>
        <mixed-citation publication-type="journal"><person-group><name><surname>Coates</surname><given-names>J. R.</given-names></name><name><surname>Barone</surname><given-names>G.</given-names></name><name><surname>Dewey</surname><given-names>C. W.</given-names></name><name><surname>Vitale</surname><given-names>C. L.</given-names></name><name><surname>Holloway-Azene</surname><given-names>N. M.</given-names></name><name><surname>Sessions</surname><given-names>J. K.</given-names></name></person-group><year>2007</year>
<article-title>Procarbazine as adjunctive therapy for
treatment of dogs with presumptive antemorterm diagnosis of granulomatous
meningoencephalomyelitis: 21 cases (1988&#x2013;2004)</article-title>. <source><italic>J. Vet.
Intern. Med.</italic></source><volume>21</volume>:
<fpage>100</fpage>&#x2013;<lpage>106</lpage>
<pub-id pub-id-type="pmid">17338156</pub-id></mixed-citation>
      </ref>
      <ref id="r7">
        <label>7</label>
        <mixed-citation publication-type="book"><person-group><name><surname>Dewey</surname><given-names>C. W.</given-names></name></person-group><year>2008</year> Encephalopathies: Disorders of the brain. pp. 190&#x2013;191.
<italic>In</italic>: A Practical Guide to Canine and Feline Neurology, 2nd ed. (Dewey,
C.W., eds.), Wiley-Blackwell, Iowa.</mixed-citation>
      </ref>
      <ref id="r8">
        <label>8</label>
        <mixed-citation publication-type="journal"><person-group><name><surname>Fellman</surname><given-names>C. L.</given-names></name><name><surname>Stokes</surname><given-names>J. V.</given-names></name><name><surname>Archer</surname><given-names>T. M.</given-names></name><name><surname>Pinchuk</surname><given-names>L. M.</given-names></name><name><surname>Lunsford</surname><given-names>K. V.</given-names></name><name><surname>Mackin</surname><given-names>A. J.</given-names></name></person-group><year>2011</year>
<article-title>Cyclosporine A affects the <italic>in
vitro</italic> expression of T cell activation-related molecules and cytokines in
dogs</article-title>. <source><italic>Vet. Immunol.
Immunopathol.</italic></source><volume>140</volume>:
<fpage>175</fpage>&#x2013;<lpage>180</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.vetimm.2010.11.005</pub-id><pub-id pub-id-type="pmid">21227512</pub-id></mixed-citation>
      </ref>
      <ref id="r9">
        <label>9</label>
        <mixed-citation publication-type="journal"><person-group><name><surname>Gnirs</surname><given-names>K.</given-names></name></person-group><year>2006</year>
<article-title>Cyclosporin treatment of suspected
granulomatous meningoencephalomyelitis in three dogs</article-title>. <source><italic>J.
Small Anim. Pract.</italic></source><volume>47</volume>:
<fpage>201</fpage>&#x2013;<lpage>206</lpage>. doi: <pub-id pub-id-type="doi">10.1111/j.1748-5827.2006.00065.x</pub-id><pub-id pub-id-type="pmid">16573763</pub-id></mixed-citation>
      </ref>
      <ref id="r10">
        <label>10</label>
        <mixed-citation publication-type="journal"><person-group><name><surname>Jung</surname><given-names>D. I.</given-names></name><name><surname>Kim</surname><given-names>J. W.</given-names></name><name><surname>Park</surname><given-names>H. M.</given-names></name></person-group><year>2012</year>
<article-title>Long-term immunosuppressive therapy with
cyclosporine plus prednisolone for necrotizing meningoencephalitis in a pekingese
dog</article-title>. <source><italic>J. Vet. Med.
Sci.</italic></source><volume>74</volume>: <fpage>765</fpage>&#x2013;<lpage>769</lpage>.
doi: <pub-id pub-id-type="doi">10.1292/jvms.11-0468</pub-id><pub-id pub-id-type="pmid">22214856</pub-id></mixed-citation>
      </ref>
      <ref id="r11">
        <label>11</label>
        <mixed-citation publication-type="journal"><person-group><name><surname>Jung</surname><given-names>D. I.</given-names></name><name><surname>Kang</surname><given-names>B. T.</given-names></name><name><surname>Park</surname><given-names>C.</given-names></name><name><surname>Yoo</surname><given-names>J. H.</given-names></name><name><surname>Gu</surname><given-names>S. H.</given-names></name><name><surname>Jeon</surname><given-names>H. W.</given-names></name><name><surname>Kim</surname><given-names>J. W.</given-names></name><name><surname>Heo</surname><given-names>R. Y.</given-names></name><name><surname>Sung</surname><given-names>H. J.</given-names></name><name><surname>Eom</surname><given-names>K. D.</given-names></name><name><surname>Lee</surname><given-names>J. H.</given-names></name><name><surname>Woo</surname><given-names>E. J.</given-names></name><name><surname>Park</surname><given-names>H. M.</given-names></name></person-group><year>2007</year>
<article-title>A comparison of combination therapy
(cyclosporine plus prednisolone) with sole prednisolone therapy in 7 dogs with
necrotizing meningoencephalitis</article-title>. <source><italic>J. Vet. Med.
Sci.</italic></source><volume>69</volume>: <fpage>1303</fpage>&#x2013;<lpage>1306</lpage>.
doi: <pub-id pub-id-type="doi">10.1292/jvms.69.1303</pub-id><pub-id pub-id-type="pmid">18176031</pub-id></mixed-citation>
      </ref>
      <ref id="r12">
        <label>12</label>
        <mixed-citation publication-type="journal"><person-group><name><surname>Kitagawa</surname><given-names>M.</given-names></name><name><surname>Okada</surname><given-names>M.</given-names></name><name><surname>Kanayama</surname><given-names>K.</given-names></name><name><surname>Sato</surname><given-names>T.</given-names></name><name><surname>Sakai</surname><given-names>T.</given-names></name></person-group><year>2007</year>
<article-title>A canine case of necrotizing
meningoencephalitis for long-term observation: clinical and MRI
findings</article-title>. <source><italic>J. Vet. Med.
Sci.</italic></source><volume>69</volume>: <fpage>1195</fpage>&#x2013;<lpage>1198</lpage>.
doi: <pub-id pub-id-type="doi">10.1292/jvms.69.1195</pub-id><pub-id pub-id-type="pmid">18057839</pub-id></mixed-citation>
      </ref>
      <ref id="r13">
        <label>13</label>
        <mixed-citation publication-type="journal"><person-group><name><surname>Matsuki</surname><given-names>N.</given-names></name><name><surname>Takahashi</surname><given-names>M.</given-names></name><name><surname>Yaegashi</surname><given-names>M.</given-names></name><name><surname>Tamahara</surname><given-names>S.</given-names></name><name><surname>Ono</surname><given-names>K.</given-names></name></person-group><year>2009</year>
<article-title>Serial examinations of anti-GFAP
autoantibodies in cerebrospinal fluids in canine necrotizing
meningoencephalitis</article-title>. <source><italic>J. Vet. Med.
Sci.</italic></source><volume>71</volume>: <fpage>99</fpage>&#x2013;<lpage>100</lpage>. doi: <pub-id pub-id-type="doi">10.1292/jvms.71.99</pub-id><pub-id pub-id-type="pmid">19194083</pub-id></mixed-citation>
      </ref>
      <ref id="r14">
        <label>14</label>
        <mixed-citation publication-type="journal"><person-group><name><surname>Matsuki</surname><given-names>N.</given-names></name><name><surname>Fujiwara</surname><given-names>K.</given-names></name><name><surname>Tamahara</surname><given-names>S.</given-names></name><name><surname>Uchida</surname><given-names>K.</given-names></name><name><surname>Matsunaga</surname><given-names>S.</given-names></name><name><surname>Nakayama</surname><given-names>H.</given-names></name><name><surname>Doi</surname><given-names>K.</given-names></name><name><surname>Ogawa</surname><given-names>H.</given-names></name><name><surname>Ono</surname><given-names>K.</given-names></name></person-group><year>2004</year>
<article-title>Prevalence of autoantibody in
cerebrospinal fluids from dogs with various CNS diseases</article-title>.
<source><italic>J. Vet. Med. Sci.</italic></source><volume>66</volume>:
<fpage>295</fpage>&#x2013;<lpage>297</lpage>. doi: <pub-id pub-id-type="doi">10.1292/jvms.66.295</pub-id><pub-id pub-id-type="pmid">15107560</pub-id></mixed-citation>
      </ref>
      <ref id="r15">
        <label>15</label>
        <mixed-citation publication-type="journal"><person-group><name><surname>Munana</surname><given-names>K. R.</given-names></name><name><surname>Luttgen</surname><given-names>P. J.</given-names></name></person-group><year>1998</year>
<article-title>Prognostic factors for dogs with
granulomatous meningoencephalomyelitis: 42 cases (1982&#x2013;1996)</article-title>.
<source><italic>J. Am. Vet. Med. Assoc.</italic></source><volume>212</volume>:
<fpage>1902</fpage>&#x2013;<lpage>1906</lpage>
<pub-id pub-id-type="pmid">9638190</pub-id></mixed-citation>
      </ref>
      <ref id="r16">
        <label>16</label>
        <mixed-citation publication-type="journal"><person-group><name><surname>Robson</surname><given-names>D.</given-names></name></person-group><year>2003</year>
<article-title>Review of the pharmacokinetics,
interactions and adverse reactions of cyclosporine in people, dogs and
cats</article-title>. <source><italic>Vet. Rec.</italic></source><volume>152</volume>:
<fpage>739</fpage>&#x2013;<lpage>748</lpage>. doi: <pub-id pub-id-type="doi">10.1136/vr.152.24.739</pub-id><pub-id pub-id-type="pmid">12833934</pub-id></mixed-citation>
      </ref>
      <ref id="r17">
        <label>17</label>
        <mixed-citation publication-type="journal"><person-group><name><surname>Sarfaty</surname><given-names>D.</given-names></name><name><surname>Carrillo</surname><given-names>J. M.</given-names></name><name><surname>Greenlee</surname><given-names>P. G.</given-names></name></person-group><year>1986</year>
<article-title>Differential diagnosis of granulomatous
meningoencephalomyelitis, distemper, and suppurative meningoencephalitis in the
dog</article-title>. <source><italic>J. Am. Vet. Med.
Assoc.</italic></source><volume>188</volume>: <fpage>387</fpage>&#x2013;<lpage>392</lpage>
<pub-id pub-id-type="pmid">3949614</pub-id></mixed-citation>
      </ref>
      <ref id="r18">
        <label>18</label>
        <mixed-citation publication-type="journal"><person-group><name><surname>Shibuya</surname><given-names>M.</given-names></name><name><surname>Matsuki</surname><given-names>N.</given-names></name><name><surname>Fujiwara</surname><given-names>K.</given-names></name><name><surname>Imajoh-ohmi</surname><given-names>S.</given-names></name><name><surname>Fukuda</surname><given-names>H.</given-names></name><name><surname>Tpham</surname><given-names>N.</given-names></name><name><surname>Tamahara</surname><given-names>S.</given-names></name><name><surname>Ono</surname><given-names>K.</given-names></name></person-group><year>2007</year>
<article-title>Autoantibodies against glial fibrillary
acidic protein (GFAP) in cerebrospinal fluids from Pug dogs with necrotizing
meningoencephalitis</article-title>. <source><italic>J. Vet. Med.
Sci.</italic></source><volume>69</volume>: <fpage>241</fpage>&#x2013;<lpage>245</lpage>.
doi: <pub-id pub-id-type="doi">10.1292/jvms.69.241</pub-id><pub-id pub-id-type="pmid">17409638</pub-id></mixed-citation>
      </ref>
      <ref id="r19">
        <label>19</label>
        <mixed-citation publication-type="journal"><person-group><name><surname>Steffan</surname><given-names>J.</given-names></name><name><surname>Strehlau</surname><given-names>G.</given-names></name><name><surname>Maurer</surname><given-names>M.</given-names></name><name><surname>Rohlfs</surname><given-names>A.</given-names></name></person-group><year>2004</year>
<article-title>Cyclosporin A pharmacokinetics and
efficacy in the treatment of atopic dermatitis in dogs</article-title>.
<source><italic>J. Vet. Pharmacol. Ther.</italic></source><volume>27</volume>:
<fpage>231</fpage>&#x2013;<lpage>238</lpage>. doi: <pub-id pub-id-type="doi">10.1111/j.1365-2885.2004.00587.x</pub-id><pub-id pub-id-type="pmid">15305852</pub-id></mixed-citation>
      </ref>
      <ref id="r20">
        <label>20</label>
        <mixed-citation publication-type="journal"><person-group><name><surname>Suzuki</surname><given-names>M.</given-names></name><name><surname>Uchida</surname><given-names>K.</given-names></name><name><surname>Morozumi</surname><given-names>M.</given-names></name><name><surname>Hasegawa</surname><given-names>T.</given-names></name><name><surname>Yanai</surname><given-names>T.</given-names></name><name><surname>Nakayama</surname><given-names>H.</given-names></name><name><surname>Tateyama</surname><given-names>S.</given-names></name></person-group><year>2003</year>
<article-title>A comparative pathology study on canine
necrotizing meningoencephalitis and granulomatous
meningoencephalomyelitis</article-title>. <source><italic>J. Vet. Med.
Sci.</italic></source><volume>65</volume>: <fpage>1233</fpage>&#x2013;<lpage>1239</lpage>.
doi: <pub-id pub-id-type="doi">10.1292/jvms.65.1233</pub-id><pub-id pub-id-type="pmid">14665754</pub-id></mixed-citation>
      </ref>
      <ref id="r21">
        <label>21</label>
        <mixed-citation publication-type="journal"><person-group><name><surname>Thomas</surname><given-names>W. B.</given-names></name></person-group><year>1998</year>
<article-title>Inflammatory diseases of the central
nervous system in dogs</article-title>. <source><italic>Clin. Tech. Small Anim.
Pract.</italic></source><volume>13</volume>: <fpage>167</fpage>&#x2013;<lpage>178</lpage>.
doi: <pub-id pub-id-type="doi">10.1016/S1096-2867(98)80038-8</pub-id><pub-id pub-id-type="pmid">9775507</pub-id></mixed-citation>
      </ref>
      <ref id="r22">
        <label>22</label>
        <mixed-citation publication-type="journal"><person-group><name><surname>Thomas</surname><given-names>W. B.</given-names></name></person-group><year>1999</year>
<article-title>Nonneoplastic disorders of the
brain</article-title>. <source><italic>Clin. Tech. Small Anim.
Pract.</italic></source><volume>14</volume>: <fpage>125</fpage>&#x2013;<lpage>147</lpage>.
doi: <pub-id pub-id-type="doi">10.1016/S1096-2867(99)80030-9</pub-id><pub-id pub-id-type="pmid">10457657</pub-id></mixed-citation>
      </ref>
      <ref id="r23">
        <label>23</label>
        <mixed-citation publication-type="journal"><person-group><name><surname>Zarfoss</surname><given-names>M.</given-names></name><name><surname>Schatzberg</surname><given-names>S.</given-names></name><name><surname>Venator</surname><given-names>K.</given-names></name><name><surname>Cutter-Schatzberg</surname><given-names>K.</given-names></name><name><surname>Cuddon</surname><given-names>P.</given-names></name><name><surname>Pintar</surname><given-names>J.</given-names></name><name><surname>Weinkle</surname><given-names>T.</given-names></name><name><surname>Scarlett</surname><given-names>J.</given-names></name><name><surname>DeLahunta</surname><given-names>A.</given-names></name></person-group><year>2006</year>
<article-title>Combined cytosine arabinoside and
prednisolone therapy for meningoencephalitis of unknown aetiology in 10
dogs</article-title>. <source><italic>J. Small Anim.
Pract.</italic></source><volume>47</volume>: <fpage>588</fpage>&#x2013;<lpage>595</lpage>.
doi: <pub-id pub-id-type="doi">10.1111/j.1748-5827.2006.00172.x</pub-id><pub-id pub-id-type="pmid">17004951</pub-id></mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
